ACRX - アセルRX・ファ―マシュ―ティカルズ （AcelRx Pharmaceuticals Inc.） アセルRX・ファ―マシュ―ティカルズACRXのチャート
ACRXの企業情報
| symbol | ACRx |
|---|---|
| 会社名 | AcelRx Pharmaceuticals Inc （アセルRX・ファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 AcelRx Pharmaceuticals Inc. is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment which includes development and commercialization of product candidates for the treatment of pain. Its lead product candidates include ARX-04 Zalviso which utilize sublingual sufentanil delivered through a non-invasive route of administration and ARX-03. ARX-04 is meant for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional to a patient in medically supervised settings. Zalviso is meant for the management of moderate-to-severe acute pain in hospitalized adult patients. ARX-03 provides mild sedation anxiety reduction and pain relief for patients undergoing painful procedures in a physician''s office. It also includes ARX-02 which is meant for the treatment of patients who suffer from breakthrough pain (BTP) due to cancer. アセルRX・ファ―マシュ―ティカルズは米国の医薬品会社。急性疼痛や突出痛用の治療薬の開発と商業化に重点を置く。候補薬には入院患者向け急性痛自己治療システム｢Zalviso｣、および救急処置室や救急病院用の中度・重度疼痛治療のスフェンタニルナノ粒子錠剤がある。本社はカリフォルニア州。 |
| 本社所在地 | 351 Galveston Drive Redwood City CA 94063 USA |
| 代表者氏名 | Adrian Adams エイドリアンアダムス |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 650-216-3500 |
| 設立年月日 | 38534 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2011年 |
| 従業員数 | 41人 |
| url | www.acelrx.com |
| nasdaq_url | https://www.nasdaq.com/symbol/acrx |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -31.00100 |
| 終値（lastsale） | 2.99 |
| 時価総額（marketcap） | 181193742.86 |
| 時価総額 | 時価総額（百万ドル） 160.58980 |
| 売上高 | 売上高（百万ドル） 3.38800 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 215.42480 |
| 当期純利益 | 当期純利益（百万ドル） -10.92800 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 AcelRx Pharmaceuticals Inc revenues decreased 80% to $1.2M. Net loss decreased 23% to $22.1M. Revenues reflect Collaboration agreement revenue decrease of 88% to $625K Contract and other decrease of 2% to $536K. Lower net loss reflects Research and development - Balancing val decrease of 45% to $6M (expense) General and Administrative - Balancing v decrease of 6% to $6.8M (expense). |
ACRXのテクニカル分析
ACRXのニュース
AcelRx Pharmaceuticals Announces Publication of Clinical Data on Decreased Postoperative Opioid Requirements and Enhanced Postanesthesia Recovery Following Perioperative Use of DSUVIA® 2020/12/10 14:00:00 PR Newswire
REDWOOD CITY, Calif., Dec. 10, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the publication by the…
AcelRx Pharmaceuticals Announces Partnership with the National Rural Health Association 2020/12/04 13:30:00 PR Newswire
REDWOOD CITY, Calif., Dec. 4, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced a partnership with the…
AcelRx Pharmaceuticals Announces Commentary in Practical Pain Management on Previously Published Clinical Data on Preoperative Administration of DSUVIA® 2020/11/18 13:30:00 PR Newswire
REDWOOD CITY, Calif., Nov. 18, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the recent publication by…
AcelRx Pharmaceuticals Reports Third Quarter 2020 Financial Results 2020/11/05 21:05:00 PR Newswire
REDWOOD CITY, Calif., Nov. 5, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported its third quarter…
AcelRx to Host Third Quarter 2020 Financial Results Call and Webcast on Thursday, November 5, 2020 2020/10/29 20:05:00 PR Newswire
REDWOOD CITY, Calif., Oct. 29, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release third quarter financial results after market close on Thursday, November 5, 2020. AcelRx management will host a live…
AcelRx Pharmaceuticals Announces Commentary in Practical Pain Management on Previously Published Clinical Data on Preoperative Administration of DSUVIA® 2020/11/18 13:30:00 PR Newswire
REDWOOD CITY, Calif., Nov. 18, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the recent publication by…
AcelRx Pharmaceuticals Reports Third Quarter 2020 Financial Results 2020/11/05 21:05:00 PR Newswire
REDWOOD CITY, Calif., Nov. 5, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported its third quarter…
AcelRx to Host Third Quarter 2020 Financial Results Call and Webcast on Thursday, November 5, 2020 2020/10/29 20:05:00 PR Newswire
REDWOOD CITY, Calif., Oct. 29, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release third quarter financial results after market close on Thursday, November 5, 2020. AcelRx management will host a live…
AcelRx Pharmaceuticals (NASDAQ:ACRX) Trading Up 9.5% 2020/10/22 19:30:42 The Olympia Report
Shares of AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) were up 9.5% during mid-day trading on Thursday . The stock traded as high as $1.90 and last traded at $1.85. Approximately 1,529,201 shares were traded during mid-day trading, an increase of 21% from the average daily volume of 1,260,784 shares. The stock had previously closed at $1.69. Several […]
Pain Management- New Discoveries And Treatment Options In Abuse Deterrent Era | AbbVie, AcelRx Pharma, Acorda Therapeutics 2020/10/01 15:01:15 OpenPR
The research report on Pain Management Market provides a comprehensive analysis of the market status and development trend, including types, applications, growth, opportunities, rising technology, competitive landscape and product offerings of key players. Pain Management Market report covers the present
AcelRx Pharmaceuticals Reports Third Quarter 2020 Financial Results 2020/11/05 21:05:00 PR Newswire
REDWOOD CITY, Calif., Nov. 5, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported its third quarter…
AcelRx to Host Third Quarter 2020 Financial Results Call and Webcast on Thursday, November 5, 2020 2020/10/29 20:05:00 PR Newswire
REDWOOD CITY, Calif., Oct. 29, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release third quarter financial results after market close on Thursday, November 5, 2020. AcelRx management will host a live…
AcelRx Pharmaceuticals (NASDAQ:ACRX) Trading Up 9.5% 2020/10/22 19:30:42 The Olympia Report
Shares of AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) were up 9.5% during mid-day trading on Thursday . The stock traded as high as $1.90 and last traded at $1.85. Approximately 1,529,201 shares were traded during mid-day trading, an increase of 21% from the average daily volume of 1,260,784 shares. The stock had previously closed at $1.69. Several […]
Pain Management- New Discoveries And Treatment Options In Abuse Deterrent Era | AbbVie, AcelRx Pharma, Acorda Therapeutics 2020/10/01 15:01:15 OpenPR
The research report on Pain Management Market provides a comprehensive analysis of the market status and development trend, including types, applications, growth, opportunities, rising technology, competitive landscape and product offerings of key players. Pain Management Market report covers the present
AcelRx to Host Virtual KOL Event on Perioperative Use of DSUVIA® 2020/09/29 12:30:00 PR Newswire
REDWOOD CITY, Calif., Sept. 29, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced it will host a…